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Abstract
Over the years, numerous mechanisms have been identified through which homocys-
teine affects osteoblast functioning. These include alterations in collagen structure, epi-
genetic modifications and changes in RANKL-OPG production by osteoblasts. These 
mechanisms are reviewed in this chapter. We have also herein discussed how homocys-
teine affects osteocyte behavior. With onset of hyperhomocysteinemia induction of osteo-
cyte specific genes particularly the mineralization genes like Dmp1 and Sost is facilitated 
producing untoward mineralization, osteocyte apoptosis, deviations from regular bone 
remodeling process and onset of targeted remodeling in bone. These modifications have 
immense effect on the overall mechanical stability of bone. Homocysteine thus represents 
an independent risk factor for bone fragility.
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1. Introduction
Bone remodelling is a process that occurs throughout life. This process occurs to replace old 
mineralized bone with new bone, preserve bone mass, mineral homeostasis, pH balance, repair 
microdamage, maintain glucose homeostasis and preserve male fertility. Bone remodeling is a 
highly co-ordinated process that requires the controlled activities of many systemic and local 
factors like calcitriol, parathyroid hormone, growth hormone, thyroid hormones, glucocorti-
coids, bone morphogenetic proteins, prostaglandins, sex hormones, various cytokines and the 
molecular triad comprising of OPG (osteoprotegerin), receptor activator of nuclear factor-κB 
ligand (RANKL) and receptor activator of nuclear factor-κB (RANK). The cells involved in the 
process are osteoblasts, osteoclasts, osteocytes, immune cells, megakaryocytes and osteomacs. 
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With senescence, decreased production of sex hormones like estrogen and testosterone, sus-
ceptibility to genetic and environmental factors and life style modifications; the process of bone 
remodeling process gets hampered increasing the rate of bone resorption as compared to that 
of bone formation. Such deviations from normal bone remodeling process deplete the bone of 
its minerals like calcium and proteins like collagen affecting the overall mass and mechanical 
property of the bone, escalating the risk of bone fractures [1, 2].
Many metabolic substances also affect bone. One such factor is homocysteine. Since its dis-
covery in 1932, homocysteine has remained an important aspect for research. Homocysteine 
is basically a metabolite of methionine metabolism that exists at a critical biochemical point in 
the methionine cycle from where it is used to synthesize cysteine and glutathione. When re-
methylation and transsulfuration cycles in methionine cycle collapse owing to an enzyme or 
co-factor deficiency, homocysteine accumulate in blood resulting in a clinical condition called 
hyperhomocysteinemia (>15 micromol/L). The prevalence of hyperhomocysteinemia varies 
with geography, age, sex and ethnicity. Till date high level of methionine, deficiency of enzymes 
in methionine metabolism like cystathionine synthase (a pyridoxal phosphate dependent 
enzyme), methionine synthase (a folate and vitamin B12 dependent enzyme) and methylene-
tetrahydrofolate reducatase, deficiency of vitamins like folate and vitamin B12 in diet (caused by losses of these sensitive vitamins by methods of food processing such as milling of grains, 
canning, extraction of sugars and oils, radiation and chemical additives), environmental ele-
ments, life-style habits, hormonal changes, drugs and diseases like cardiovascular, cancer and 
type 2 diabetes have been found to be causes for hyperhomocysteinemia.
The negative effect of homocysteine on the bone is well supported by the demonstrations 
of loss of bone physiology in experimental animals of hyperhomocysteinemia generated 
by administering a methionine-enriched diet (with low folate) as well in genetic models of 
enzyme deficiency [3]. This chapter will present the current findings on how hyperhomo-
cysteinemia alters the functions of two types of bone cells—the osteoblast and the osteocyte.
1.1. How homocysteine affects osteoblast function?
Studies on the effect of homocysteine on bone forming osteoblasts have shown that homo-
cysteine is different from a conventional oxidant and exerts its effects on cells via multiple 
modes. Over the years diverse mechanisms were identified by which homocysteine affects 
osteoblast functioning. These include alterations in collagen structure, epigenetic modifica-
tions and changes in RANKL-OPG production by osteoblasts. The first example to cite how 
homocysteine alters osteoblast machinery was a clinical study by Hermann et al. in 2005 [4]. 
The results of this study showed that a positive correlation occurs between hyperhomocyste-
inemia and circulating concentrations of osteocalcin, an osteoblast activity marker. In contrast 
to this finding was a report by Sakamoto et al. in the same year 2005 [5], which demonstrated 
that homocysteine, stimulates only osteopontin and has an attenuating effect on osteocalcin. 
The paper also revealed that homocysteine represents an independent risk factor for osteopo-
rosis. In the subsequent years 2007–2008, clinical studies by Hermann et al. [6, 7] published 
the following: Accumulation of homocysteine caused by “reduction in co-factors of methionine 
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metabolism like folate, vitamin B12 and vitamin B6” do not cause any change in the activities of alkaline phosphatase, osteocalcin and pro-collagen type I N-terminal peptide (PINP) in 
serum. However such low concentrations of folate, vitamin B12 and vitamin B6 are enough to produce a stimulatory effect on osteoclast activity. This study also rationalized the mechanis-
tic role of low B-vitamin concentrations for bone degradation. The same research group also 
demonstrated how direct exposure of primary human osteoblasts to increasing concentra-
tions of homocysteine stimulates cellular activity. This report brought about the awareness 
that homocysteine “not inhibits but alters” osteoblast function, one of the reasons why some 
of results of clinical and experimental studies were in disagreement with each other. In the 
subsequent years Thaler et al. [8–10] reported noteworthy mechanisms regarding how homo-
cysteine affected the bone matrix. The authors showed that homocysteine altered collagen 
cross linking by inhibiting the expression of lysyl hydroxylase and lysyl oxidase, enzymes 
required for formation of stable bone matrix. Collagen cross linking in the bone is a post trans-
lational modification of collagen molecules that play integral role in tissue differentiation and 
render mechanical support to the bone. The authors revealed that homocysteine uncovers 
RGD motif (a tripeptide of Arg-Gly-Asp) in collagen by RelA protein activation. Collagens 
are important structural proteins that form the extracellular matrix and play important role in 
shaping and organizing a tissue and the major collagen found in the bone is type 1 collagen. 
When denatured, type 1 collagen unwinds its triple helical structure causing the exposure 
of RGD motifs in it. Such exposure is basically a mechanism by which signals are presented 
to cells for regulating cell behavior, promoting tissue repair and regeneration. But when 
exposed to homocysteine such RGD exposure elicits serum amyloid A3 expression and over-
expression of matrix degrading enzymes and cytokines like MMP-13 (metalloproteinase-13), 
Ccl5, Ccl2, Cxcl10 and interleukin-6, substances otherwise known to hamper the proper col-lagen cross linking of bone matrix [10]. This group also reported that homocysteine increased 
the expression of genes for epigenetic DNA methylation like cytosine-5-methyl transferases1 
(Dnmt1) and lymphoid specific helicase. The mechanism was found to be by increasing the 
expression of Fli1 (Friend leukemia virus integration 1), a transcription factor important for 
Dnmt1 stimulation. The authors also discovered that homocysteine caused hypermethylation 
of Lox (lysyl oxidase) proximal promoter that caused Lox repression. Lox is an extracellular 
copper dependent enzyme that catalyzes the formation of aldehydes from lysine residues in 
collagen precursors. In 2011, Lv et al. [11] reported a similar hypermethylation effect of homo-
cysteine on promoter A region of estrogen receptor-alpha that cause repression of estrogen 
receptor alpha expression. The authors concluded that such inhibitory mechanisms can elicit 
postmenopausal osteoporosis in women, a bone disorder encountered by most females upon 
menopause. It was in the same year that Kriebitzsc et al. [12] established a link between homo-
cysteine and vitamin D3. A microarray experiment by these authors on MC3T3-E1 murine 
pre-osteoblasts treated with 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) revealed the induction of a cluster of genes including the cbs (cystathionine β-synthase gene). Since CBS is an enzyme 
that converts homocysteine to cystathionine, thereby committing transsulfuration pathway to 
cysteine synthesis, the authors were intrigued to find out how vitamin D3 regulated the level 
of homocysteine in the osteoblast. They then discovered that Cbs mRNA levels were very 
much higher when osteoblasts obtained sufficient exposure to vitamin D3. Importantly, the 
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chromatin immunoprecipitation on chip and transfection studies demonstrated a functional 
vitamin D response element in the second intron of cbs. The possible clinical relevance of 
these findings were investigated by these authors, and the human data from the Longitudinal 
Aging Study Amsterdam suggested a correlation between vitamin D status (25(OH)D3 levels) and homocysteine levels. The authors drew conclusions that cbs is a primary 1,25(OH)
2
D3 target gene which renders homocysteine metabolism responsive to 1,25(OH)
2
D3.
In 2012, the role of homocysteine mediated endoplasmic reticulum (ER) stress in inducing 
apoptosis was reported revealing that osteoblast death can also occur during hyperhomo-
cysteinemia. Homocysteine increases the expression of glucose-regulated protein 78, inosi-
tol-requiring transmembrane kinase and endonuclease 1α (IRE-1α), spliced X-box binding 
protein, activating transcription factor 4, and C/EBP homologous protein to carry out cell 
death [13].
Our group in 2013 reported how homocysteine altered the production of proteins in osteo-
blasts [14]. We were mainly interested in evaluating how homocysteine affected the synthe-
sis of ligands like RANKL and OPG by osteoblasts. Proteins like RANKL, OPG and RANK 
(receptor on osteoclast) form a molecular trio which is one of the important regulators of 
bone remodeling. RANKL is required for RANK activation, development of multi-nucle-
ated osteoclasts and induction of bone resorption. To regulate the osteoclast activity, the 
osteoblast also synthesizes OPG that serves as a decoy receptor for RANKL that binds it 
and prevents it from activating RANK. Our studies on how homocysteine affected the syn-
thesis of OPG also threw light that this ligand production in osteoblast is coupled to the 
insulin-MAPK (mitogen activated protein kinase) signaling cascade and antioxidant defense 
machinery. The dephosphorylations of insulin receptor and associated downstream targets 
caused by homocysteine induce phosphorylation of PP2A (protein phosphatase 2A), a nega-
tive modulator of the insulin signaling. This increase in phosphatase activity also inhibited 
phosphorylation of p38 mitogen activated protein kinase, a pathway important for OPG 
synthesis by osteoblast cells. We were intrigued to find that dephosphorylations of insulin 
receptor signaling also produced increased nuclear translocation of ForkheadO1 transcrip-
tion factor and activation of MnSod (manganese superoxide dismutase), an antioxidant. The 
RANKL synthesis however occurred independently and involved activation of c-Jun/JNK 
MAP kinase (JNK) signaling pathway. Thus the oxidative stress imparted by homocyste-
ine altered the osteoblast behavior shifting the balance between bone formation and bone 
resorption.
1.2. Does homocysteine affect osteocytogenesis?
Osteocyte represents the third major cell type in the bone, which regulates the functions of 
osteoblasts and osteoclasts. These cells originate from mesenchymal stem cells via osteo-
blast lineage differentiation, and only 10–20% of such osteoblasts develop into osteocytes. 
Osteocytes also have an extraordinary long-life of 10–20 years and consequently constitute 
95% of the cellular component of adult living bone. Mature osteocytes inhabit in cavities 
called “osteocyte lacunae” measuring some hundreds of μm3 in volume that shape into an 
interconnected network via tiny canals or canaliculi to form the lacunar-canalicular pore 
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system (LCS). LCS buried within the mineralized matrix positions osteocytes to derive nutri-
ents from the blood supply, feel external mechanical signals, connect among themselves 
and with other cells on bone surfaces and control structural reorganization following bone 
remodeling [15, 16]. It was formerly thought that osteocytes are inert cells, however these 
are now contemplated to be superior cell type with endocrine functions. Upon stimulation, 
osteocytes secrete substances like RANK ligand, OPG, fibroblast growth factor23 (FGF23), 
prostanoids, nitric oxide, nucleotides, cytokines and growth factors that regulate bone 
remodeling. FGF23 produced by osteocytes regulate serum phosphate level by increasing 
renal phosphate excretion. Sclerostin and DKK1 specifically inhibit Wnt-B-catenin pathway 
that regulate bone formation [17, 18].
The process of “osteocytogenesis” is the evolution of a bone forming osteoblast to an osteocyte 
when it gets deeply buried in the bone matrix. The process involves three different phases: 
(i) type I osteoblastic-osteocyte, (ii) type II osteoid-osteocyte and (iii) type III preosteocyte 
(surrounded by matrix) [19]. Some of the noteworthy proteins involved in the process are: (a) 
Pdpn (E11), a trans-membrane glycoprotein that is required for the formation of dendrites, (b) 
osteocalcin, a non-collagenous protein for proper mineralization of marix, (c) dentine matrix 
protein or Dmp1 for regulation of crystal mineral size and osteocyte maturation [17, 20], (d) 
Phex, a metalloproteinase that binds to the inhibitor of Dmp1 viz. MEPE and regulates Dmp1 
activity, (e) AHSG or FetuinA which regulates mineralization around developing osteocytes 
[21, 22] and (f) Sclerostin, a regulator of bone remodeling which can inhibit bone formation 
via downregulation of Wnt Lrp5/6 signaling, the major anabolic pathway in bone, which can 
activate osteoclasts and regulate mineralization [18, 23].
Till date there are only few reports that substantiate that osteocytes affected during hyperho-
mocysteinemia. One of the reasons for this is the difficulty in isolating osteocytes from min-
eralized tissues for obtaining these in sufficient numbers and purity. Over the years a cell line 
MLO-Y4 was developed by Lynda F Bonewald and many methods to isolate osteocytes from 
bone tissue were developed but none gave a complete picture as to how osteocytes responded 
to external stimuli. This is mainly because both the osteocytes and its extensive connections 
are not possible to be replicated in concert in vitro. Yet, investigations have been done on 
using the MLO-Y4 cell line to evaluate how osteocyte responds homocysteine. The results 
showed that homocysteine induced apoptosis in osteocyte culture via Nox and AMPK activa-
tion [24]. Nox or NADPH oxidase family of superoxide and hydrogen peroxide producing 
proteins represent an important source of reactive oxygen species whilst AMPK or adenosine 
monophosphate activated protein kinase is an energy sensor that regulates oxidative stress. 
The study by Takeno et al. did not render a complete picture as osteocytes are embedded 
deep inside the bone where it is not exposed to high concentrations of homocysteine. Thus 
we investigated how homocysteine affected osteocytes in vivo by administering mice with 
homocysteine i.p. and then evaluating how homocysteine in circulation modulated osteocytes 
employing microCT50, immunohistochemistry and Real Time PCR [25]. These techniques 
enabled us to identify time dependent changes in osteocyte lacunar numbers and osteocyte 
markers with onset of hyperhomocysteinemia. It was interesting to find that with induc-
tion of hyperhomocysteinemia, there was initially an increase in osteocyte lacunar numbers 
coupled to an increase in transcription and protein expression of many osteocyte markers. 
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But with time we observed that homocysteine mainly increased the protein expressions of 
Dmp1 and sclerostin that were otherwise involved in mineralization of osteocyte lacunae. 
This is in fact a pathogenic mechanism since increased mineralization is also a cause for bone 
instability. Another trait seen in these bone was osteocyte apoptosis. Erstwhile studies have 
previously demonstrated that apoptotic osteocytes are not “debris” but necessary regulators 
of a process called “targeted remodeling” wherein apoptotic osteocytes signal nearby cells to 
release factors like RANKL, VEGF, ATP, sphingosine-1-phosphate and chemokines for endo-
thelial cell activation and recruitment of bone cell precursors, including osteoclasts and osteo-
blasts, to the site of injury to enable repair via BMU-mediated remodeling process [26, 27]. It 
has already been shown that homocysteine induces RANKL synthesis. Thus, homocysteine 
mediated induction of RANKL production by both osteoblasts and osteocytes is therefore 
an important determinant that drives bone to rapid bone resorption and thereby increased 
bone remodeling during hyperhomocysteinemia. Our findings thus provide an interesting 
avenue for future research into the role of osteocytes in disease-mediated changes in bone 
mineralization.
2. Conclusions
The effect homocysteine has on bone remodeling is dynamic. Unlike any other oxidant that 
generates free radicals, homocysteine exerts effects at multiple ways to induce cellular dam-
age. We have seen that in some cases homocysteine induces gene methylations to render cer-
tain genes like Lox inactive so that collagen architecture is altered whereas in other cases 
homocysteine over expresses genes like Dmp and Sost to promote mineralization, a process 
that can produce adverse effects on long run. Understanding the complexities involved in 
hyperhomocysteinemia is therefore vital for designing therapeutics for treatment of bone 
disorders.
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